Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Futura Medical PLC (GB:FUM)
LSE:FUM
FUM Stock Chart & Stats
Day’s Range― - ―
52-Week Range12.80p - 45.56p
Previous CloseN/A
Volume13.08K
Average Volume (3M)976.76K
Market Cap
£43.42M
Enterprise Value113.29M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Apr 09, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding303,829,680
10 Day Avg. Volume1,193,793
30 Day Avg. Volume976,765
Standard Deviation0.38
R-Squared0.04
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.30
Price to Cash Flow (P/CF)-7.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
140.00pPrice Target Upside879.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Futura Medical News
PremiumCompany Announcements
Futura Medical Exceeds 2024 Expectations but Faces Challenges Ahead
PremiumCompany Announcements
Futura Medical Reports Positive Study Results for WSD4000
PremiumCompany Announcements
Futura Medical Reports Positive Outcomes for WSD4000 Study
PremiumCompany Announcements
Futura Medical Issues Shares for Non-Executive Director Remuneration
PremiumCompany Announcements
Futura Medical Announces Change in Major Shareholder Voting Rights
PremiumCompany Announcements
Futura Medical’s Major Shareholding Shift
PremiumCompany Announcements
Futura Medical Reveals Promising Product Pipeline ResultsPremiumCompany Announcements
Futura Medical’s Share Capital and Market Expansion---
Bulls Say, Bears Say
Bulls Say
Market OpportunityWSD4000 has the potential to be the first regulatory-approved OTC product to address female sexual dysfunction, a condition which is underserved by current treatment options.
Product DevelopmentFutura's female sexual dysfunction product, WSD4000, has delivered positive results in a home user study, which saw the product deliver an overall positive change in sexual function after four weeks.
Bears Say
Market CompetitionFutura's Eroxon product will be the only clinically proven ED treatment available without prescription in the US market, but early launch metrics show a repurchase rate estimated to be in the region of 15% to 20%, which may indicate challenges in consumer retention.
---
Options Prices
Currently, No data available
---
Ownership Overview
FUM FAQ
What was Futura Medical PLC’s price range in the past 12 months?
Futura Medical PLC lowest share price was 12.80p and its highest was 45.56p in the past 12 months.
What is Futura Medical PLC’s market cap?
Futura Medical PLC’s market cap is £43.42M.
When is Futura Medical PLC’s upcoming earnings report date?
Futura Medical PLC’s upcoming earnings report date is Apr 09, 2025 which is in 46 days.
How were Futura Medical PLC’s earnings last quarter?
Futura Medical PLC released its earnings results on Sep 10, 2024. The company reported 0.003p earnings per share for the quarter, beating the consensus estimate of N/A by 0.003p.
Is Futura Medical PLC overvalued?
According to Wall Street analysts Futura Medical PLC’s price is currently Undervalued.
Does Futura Medical PLC pay dividends?
Futura Medical PLC does not currently pay dividends.
What is Futura Medical PLC’s EPS estimate?
Futura Medical PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Futura Medical PLC have?
Futura Medical PLC has 303,829,680 shares outstanding.
What happened to Futura Medical PLC’s price movement after its last earnings report?
Futura Medical PLC reported an EPS of 0.003p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5%.
Which hedge fund is a major shareholder of Futura Medical PLC?
Currently, no hedge funds are holding shares in GB:FUM
---
Futura Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
140.00p (879.71% Upside)
140.00p (879.71% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.59%
12-Months-Change
Fundamentals
Return on Equity
-47.43%
Trailing 12-Months
Asset Growth
-7.26%
Trailing 12-Months
Company Description
Futura Medical PLC
Futura Medical PLC is a drug manufacturer based in the United Kingdom. It lays primary focus exclusively on topically applied pharmaceutical drugs and medical devices which are developed using a highly efficient and proprietary transdermal delivery technology, DermaSys. DermaSys is a versatile technology that can be customized to suit the specific active compound being used and the therapeutic indication. Futura's products are used mainly for the treatment of erectile dysfunction and pain relief.
---
FUM Stock 12 Month Forecast
Average Price Target
140.00p
▲(879.71% Upside)
Technical Analysis
Best Analysts Covering FUM
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-62.68%
reiterated a buy rating last month
Copying James Orsborne's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -62.68% per trade.
---